Adebayo Michael, Adeola O <br/><br/>
Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations.  [electronic resource] 

 -  Cell metabolism  05 2019 
 - 1135-1150.e6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1932-7420 
<br/><br/><label>Standard No.: </label>10.1016/j.cmet.2019.01.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acetates--pharmacology<br/>Animals<br/>Carcinoma, Hepatocellular--drug therapy<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Cell Survival--drug effects<br/>Child<br/>Child, Preschool<br/>Disease Models, Animal<br/>Female<br/>Glutamate-Ammonia Ligase--genetics<br/>Glutamine--metabolism<br/>Hepatocytes--metabolism<br/>Humans<br/>Infant<br/>Liver Neoplasms--drug therapy<br/>Male<br/>Mechanistic Target of Rapamycin Complex 1--antagonists & inhibitors<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Knockout<br/>Mutation<br/>Phenols--pharmacology<br/>Retrospective Studies<br/>Sirolimus--pharmacology<br/>TOR Serine-Threonine Kinases--genetics<br/>Transfection<br/>Wnt Signaling Pathway--genetics<br/>beta Catenin--genetics